Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Biotech
AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program
AbbVie has written the next chapter in its quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate for up to $1.2 billion.
Nick Paul Taylor
Aug 25, 2025 9:42am
HMNC recalibrates precision depression push after phase 2b miss
Aug 5, 2025 10:38am
AbbVie in talks over $1B Gilgamesh buyout: report
Jul 31, 2025 7:48am
Relmada dumps depression asset after slew of phase 3 failures
Jul 11, 2025 12:12pm
Alto's phase 2 depression trial misses primary efficacy endpoint
Jun 26, 2025 9:28am
Gilgamesh links psychedelic to 94% remission rate in depression
May 27, 2025 11:00am
